Thomas Gajewski

Thomas Gajewski University of Chicago
Professor
Homepage
PhD , University of Chicago (1991)

Compare

vs.

Go

Research Summary

Our laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo.

T Lymphocyte Biology

Naive T cells that have never seen antigen lack effector function and must acquire such functions through a differentiation process. Initial activation depends on engagement of the T cell receptor (TCR) as well as additional receptor/ligation interactions that influence the quantity and quality of the T cell response. Positive regulatory influences include CD28 engagement by B7, and negative regulatory processes include ligation of CTLA4 or by induction of an unresponsive state termed anergy. In addition to this quantitative level of control, T cell activation is also qualitatively influenced by exogenous cytokines that promote differentiation down distinct lineages of effector cell phenotype having specialized functions. We study the molecular and biochemical events that mediate regulation of T cells in the naive, effector, and anergic states, as well as the process of transitioning from one state to another. These experiments rely upon mutagenesis and viral transduction techniques, transgenic and knockout mice, and a variety of cellular immunology approaches.

Regulation of Anti-tumor Immunity

Recent work has suggested that most tumors express antigens that can be recognized as foreign by specific T cells. How and why tumors than grow and escape immune destruction has become a central problem in cancer biology. We hypothesize that part of the defect may be due to inappropriate T cell differentiation or the dominant effects of negative regulatory influences on T cell activation. In order to determine the factors necessary for tumor rejection when it successfully occurs, we study the rejection of immunogenic tumors in knockout mice lacking individual molecules expected to affect specific aspects of T cell activation and differentiation. To examine which factors are sufficient to induce anti-tumor immunity, we supply these factors in antigen-specific vaccination strategies to promote rejection of established tumors in mice. Successful preclinical tumor vaccine results are then applied to clinical trials in the melanoma clinic which I also direct. Other immunologic manipulations are explored in our clinical cancer immunotherapy group.

Similar Researchers

Columbia University
New York, NY
Profile
Percentiles
Citations
74th
Papers
86th
Funding
76th
Channels, Parasitology, Immunology, Genomics & Genetics, Membrane Physiology, Metabolism, Transport & Organ Function...
Columbia University
New York, NY
Profile
Percentiles
Citations
78th
Papers
79th
Funding
66th
Receptors, Signal Transduction, Drosophila, Genomics & Genetics, Animal Models of Psychiatric Disorders...
Columbia University
New York, NY
Profile
Percentiles
Citations
69th
Papers
74th
Funding
59th
Cancer, Developmental Biology, Channels, Signal Transduction, Receptors, Cell Specification & Differentiation, Cancer Biology...
Columbia University
New York, NY
Profile
Percentiles
Citations
75th
Papers
69th
Funding
57th
Immunology, Genomics & Genetics, Mouse Biology, Cancer, Nucleic Acids, Alzheimers, Developmental Biology...
Sloan-Kettering
New York, NY
Profile
Percentiles
Citations
73rd
Papers
95th
Funding
65th
Transcriptional Regulation, Cancer

Percentiles

Citations*
76th
Papers*
85th
Funding
60th
Efficiency
76th

Today's Citations vs.
Paper Publication Year*

-

Funding by Source
2012-2015

-
*Cited papers in our current database **Coming soon